Orchid Pharma Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹9.4K Cr
Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though short-term quarterly forecasts are uncertain. Orchid Pharma has shown a 15% growth in total income for 9 months FY '25 and a 26% increase in PAT over the same period last year.
From Orchid Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,002
Market Cap
₹9.4K Cr
P/E Ratio
348.0
How does Orchid Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare Orchid Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Orchid Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹238 Cr, net profit ₹24 Cr.
Full financials →📊 Revenue & Sales Performance
- →Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though short-term quarterly forecasts are uncertain.
- →Recent quarters showed 15%-20% volume growth; however, price corrections in key products have muted topline revenue growth.
- →The company is cautious about maintaining the same 20% year-on-year growth in FY '25 due to sharp spot price corrections, mainly in oral products.
- →Long-term growth remains positive with sustained volume increases and operational excellence.
- →New product launches like Enmetazobactam and Cefiderocol (commissioned by December 2026) are expected to contribute to future growth, though Cefiderocol revenue is anticipated beyond 2 years.
- →The AMS division (domestic hospital business) is investing for growth with a breakeven expected after one more year.
- →Regulatory milestones, capacity expansions, and strategic partnerships will support sustained growth and value creation.
📈 Profitability & Margins
- →Orchid Pharma has shown a 15% growth in total income for 9 months FY '25 and a 26% increase in PAT over the same period last year.
- →The company maintains a stable gross margin guidance of around 40%, plus or minus 2%.
- →They anticipate EBITDA margin expansion of approximately 100 basis points annually due to volume growth and productivity improvements.
- →Long-term growth expectation is a compound annual growth rate (CAGR) of about 20% over 3 years, though short-term yearly forecasts are uncertain due to market volatility and price corrections.
- →Price volatility affects revenue but the company focuses on healthy margins rather than volume at reduced prices.
- →No short-term forecast is given for FY '25 full-year growth; however, the longer trend remains positive.
- →AMS division expects a negative EBITDA for another year before becoming accretive.
- →The company foresees no tax payments likely for the next 4 to 5 years due to carry forward losses.
🏗️ Capital Expenditure Plans
- →No changes in capex timelines; projects on track as planned (Page 17).
- →Capex ongoing for 7ACA and Cefiderocol lines with no new expansion planned in the sterile business for the near future (Pages 10, 17).
- →Sterile capacity expanded last year and expected to serve well for the next couple of years (Page 10).
- →Cefiderocol project under construction; commissioning expected by November-December 2026 (Page 8).
- →7ACA project execution continues as planned despite delays; no material changes in PLI incentive or duration (Pages 8-9).
- →No immediate capacity expansion required for next 2 years to sustain growth (Page 13).
- →Strategic focus includes regulatory milestones, new product introductions, and AMS division expansion (Page 5).
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or planned fundraising through debt or equity in the call transcript.
- →Sunil Kumar Gupta mentions INR194 crores still in the bank from previous fundraising efforts.
- →No updates or discussions on new capital raising initiatives, neither equity nor debt, were provided.
- →The focus remains on operational execution, cost optimization, and project execution like the 7ACA project.
- →Management hasn't indicated any plans for fresh fundraising in the near term.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Orchid Pharma Ltd Q3 FY25 results?
Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though short-term quarterly forecasts are uncertain. Orchid Pharma has shown a 15% growth in total income for 9 months FY '25 and a 26% increase in PAT over the same period last year.
What is Orchid Pharma Ltd share price analysis?
Orchid Pharma Ltd currently shows a neutral. The stock trades at a P/E of 348.0 with a market cap of ₹9,439 Cr. Investors should review the full earnings analysis for detailed insights.
Is Orchid Pharma Ltd planning capital expenditure?
No changes in capex timelines; projects on track as planned (Page 17).
Keep Orchid Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.